Table 3 Treatment outcomes of biweekly Docetaxel plus ADT
Treatment outcomes | N = 42 (%) |
|---|---|
PSA response at 12 weeks | |
≥ 30% decline | 40 (95.2%) |
≥ 50% decline | 40 (95.2%) |
≥ 90% decline | 28 (66.7%) |
Objective Response Rate | 69% |
mCRPC-free survival, Median (95% CI) | 26.4 months (20.9–32.0) |
Overall Survival, Median (95% CI) | Not reached |